PET/CT May Improve Detection of Local CRC Liver Metastasis Progression - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

PET/CT May Improve Detection of Local CRC Liver Metastasis Progression

The combined imaging approach improved detection of local recurrence and extrahepatic disease during early posttreatment follow‐up for colorectal liver metastases.

  • By

  • Andrea Surnit

  • August 12, 2026

  • 3 min

Share

  • 1

    Fluorine-18 fluorodeoxyglucose PET/CT may enhance early detection of local tumor progression in colorectal liver metastases post-treatment.

  • 2

    In a study of 64 patients, disease progression was confirmed in 66% at first follow-up, with local tumor progression in 25% of cases.

  • 3

    F-18 FDG PET/CT showed greater diagnostic accuracy for local tumor progression compared to contrast-enhanced CT after treatment.

  • 4

    CEA testing was ineffective as a standalone marker, yielding false-negative results in 43% of patients with disease progression.

  • 5

    The study's limitations include its single-center design and reliance on multidisciplinary consensus for most diagnoses.

Original Source(s)

PET/CT May Improve Detection of Local CRC Liver Metastasis Progression

  • by Andrea Surnit

  • August 12, 2026

Related Content

Narrow DCIS Margins May Not Always Warrant Reexcision

An ancillary analysis found less than 2-percentage-point differences in 10-year recurrence across margin thresholds, with no statistically significant adjusted association.

First Patient Treated with Proton Therapy at Lynn Cancer Institute

The Eugene M. & Christine E. Lynn Cancer Institute at Boca Raton Regional Hospital, part of Baptist Health, reached an important milestone in the advancement of cancer care with the successful treatment of its first patient utilizing proton therapy, according to physicians at both the Institute and the hospital.

  • May 15, 2026

  • 5 min
Neoadjuvant Chemo Did Not Improve Disease-Free Survival

Phase 3 NeoCol trial adds to mixed evidence as field shifts toward biomarker-guided approaches